A241820 Stock Overview
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩25,700.00|
|52 Week High||₩64,500.00|
|52 Week Low||₩24,200.00|
|1 Month Change||-13.03%|
|3 Month Change||-47.76%|
|1 Year Change||-47.01%|
|3 Year Change||171.10%|
|5 Year Change||307.94%|
|Change since IPO||180.57%|
Recent News & Updates
|A241820||KR Medical Equipment||KR Market|
Return vs Industry: A241820 underperformed the KR Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: A241820 underperformed the KR Market which returned -14.3% over the past year.
|A241820 Average Weekly Movement||10.0%|
|Medical Equipment Industry Average Movement||5.6%|
|Market Average Movement||5.4%|
|10% most volatile stocks in KR Market||10.2%|
|10% least volatile stocks in KR Market||3.1%|
Stable Share Price: A241820 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: A241820's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control.
PCL Fundamentals Summary
|A241820 fundamental statistics|
Is A241820 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A241820 income statement (TTM)|
|Cost of Revenue||₩38.89b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.61k|
|Net Profit Margin||-63.58%|
How did A241820 perform over the long term?See historical performance and comparison
Is PCL undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A241820's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A241820's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A241820 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the KR Medical Equipment industry average.
PE vs Market: A241820 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A241820's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A241820 is overvalued based on its Price-To-Book Ratio (19.7x) compared to the KR Medical Equipment industry average (2.4x).
How is PCL forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PCL has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has PCL performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A241820 is currently unprofitable.
Growing Profit Margin: A241820 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A241820 is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare A241820's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A241820 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.1%).
Return on Equity
High ROE: A241820 has a negative Return on Equity (-199.03%), as it is currently unprofitable.
How is PCL's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A241820's short term assets (₩93.0B) exceed its short term liabilities (₩91.0B).
Long Term Liabilities: A241820's short term assets (₩93.0B) exceed its long term liabilities (₩4.8B).
Debt to Equity History and Analysis
Debt Level: A241820's net debt to equity ratio (86.5%) is considered high.
Reducing Debt: A241820's debt to equity ratio has increased from 11.9% to 425.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A241820 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A241820 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 38.8% each year.
What is PCL current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A241820's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A241820's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A241820's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A241820's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A241820 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
So-Youn Kim (50 yo)
Ms. Kim serves as Chief Executive Officer at PCL Inc.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.
PCL, Inc.'s employee growth, exchange listings and data sources
- Name: PCL, Inc.
- Ticker: A241820
- Exchange: KOSDAQ
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: ₩278.772b
- Shares outstanding: 10.48m
- Website: https://www.pclchip.com
- PCL, Inc.
- Star valley, 99
- Room No. 701
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.